Idiopathic Pulmonary Fibrosis
428
46
65
247
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
106 trials with published results (25%)
Research Maturity
247 completed trials (58% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.3%
44 terminated out of 428 trials
84.9%
-1.6% vs benchmark
12%
52 trials in Phase 3/4
43%
106 of 247 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 247 completed trials
Clinical Trials (428)
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Xenon MRI and Progressive ILD
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
Acute Effects of Oxygen Supplementation Among IPF Patients
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
BPF Genetics of ILD Study
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis
Lung MRI in the Management of Idiopathic Pulmonary Fibrosis
High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib
Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects
A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants
Skeletal Muscle Function in Interstitial Lung Disease
A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib
Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough